Form 4: Karyopharm Therapeutics EVP Reshma Rangwala Reports Stock and Option Awards

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, reports the acquisition of restricted stock units and stock options following a reverse stock split.

Summary

• Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 5,416 restricted stock units (RSUs) and 4,583 RSUs, both awarded under the 2022 Equity Incentive Plan.
• These RSUs convert into common stock on a one-for-one basis and vest in annual installments beginning February 28, 2026.
• Rangwala also acquired options to purchase 10,833 and 9,166 shares of common stock at an exercise price of $7.95, vesting in installments starting February 28, 2026, and expiring on February 27, 2035.
• The reported amounts reflect a one-for-fifteen reverse stock split that Karyopharm Therapeutics Inc. effected on February 25, 2025.
• Following these transactions, Rangwala beneficially owns 32,859 shares of common stock and 20,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating stock and option awards, which are standard compensation practices.

Positives

• The granting of RSUs and stock options to a key executive like the Chief Medical Officer can be seen as an incentive to drive company performance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The granting of equity to executives can align their interests with shareholders, potentially driving long-term value creation.

Key Dates